We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Spero Therapeutics Inc | NASDAQ:SPRO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.63 | 1.63 | 1.65 | 20 | 09:29:51 |
NEW YORK, June 17, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Spero Therapeutics, Inc. (NASDAQ: SPRO).
To receive updates on the lawsuit, fill out the form:
https://claimyourloss.com/securities/spero-therapeutics-inc-loss-submission-form/?id=28689&from=4
The lawsuit seeks to recover losses for shareholders who purchased Spero between October 28, 2021 and May 2, 2022.
Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until July 25, 2022 to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
According to a filed complaint, Spero Therapeutics, Inc. issued materially false and/or misleading statements and/or failed to disclose that: (i) the data submitted in support of the New Drug Application ("NDA") for the Company's product candidate, Tebipenem HBr, were insufficient to obtain approval from the U.S. Food and Drug Administration ("FDA"); (ii) accordingly, it was unlikely that the FDA would approve the Tebipenem HBr NDA in its current form; (iii) the foregoing would necessitate a significant workforce reduction and restructuring of Spero's operations; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
View original content:https://www.prnewswire.com/news-releases/spro-shareholder-alert-jakubowitz-law-reminds-spero-shareholders-of-a-lead-plaintiff-deadline-of-july-25-2022-301569995.html
SOURCE Jakubowitz Law
Copyright 2022 PR Newswire
1 Year Spero Therapeutics Chart |
1 Month Spero Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions